As per MRFR analysis, the India Biologic Therapy Market Size was estimated at 14.91 (USD Billion) in 2023.The India Biologic Therapy Market Industry is expected to grow from 15.7(USD Billion) in 2024 to 22.5 (USD Billion) by 2035. The India Biologic Therapy Market CAGR (growth rate) is expected to be around 3.326% during the forecast period (2025 - 2035).
Key India Biologic Therapy Market Trends Highlighted
The India Biologic Therapy Market is currently experiencing significant growth driven by several key factors. There is an increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, which has led to a higher demand for biologic therapies that offer targeted treatment options. Additionally, advancements in biotechnology and increased investment in research and development are propelling the market forward. The Indian government is promoting initiatives that support the development of biologics, further enhancing the environment for innovation in this sector.
Opportunities in the India Biologic Therapy Market are abundant, particularly in biosimilars, which are gaining popularity due to their cost-effectiveness compared to original biologics.As the regulatory framework in India becomes more conducive to the approval of these therapies, companies can explore partnerships and collaborations to bring new products to market more efficiently. Furthermore, the growing awareness among healthcare professionals and patients about the benefits and availability of biologic treatments presents a significant potential for market expansion. In recent times, there has been a marked trend towards personalized medicine in the Indian healthcare landscape.
This shift is encouraging pharmaceutical companies to focus on developing tailored biologic therapies that cater to individual patient needs. Biologic therapies are also being integrated into treatment protocols for various diseases, leading to better patient outcomes and improved quality of life.As more stakeholders recognize the importance of biologics, including healthcare providers and insurers, the overall accessibility and acceptance of these therapies are expected to increase, further boosting the market in India.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
India Biologic Therapy Market Drivers
Growing Burden of Autoimmune Disorders
In India, the prevalence of autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis has been on the rise, contributing significantly to the India Biologic Therapy Market Industry. According to the Indian Council of Medical Research, autoimmune diseases affect around 10% of the Indian population, with studies indicating that this figure has steadily increased over the last decade.
The increasing awareness and diagnosis of these conditions have led to a growing demand for biologic therapies, which are specifically designed to target and manage such diseases.Established pharmaceutical firms like Biocon and Dr. Reddy's Laboratories are actively investing in Research and Development for biologic treatments, enhancing their portfolios to meet the rising healthcare needs associated with autoimmune disorders. This focus on R&D is expected to propel market growth as more effective therapies become available to address this growing health concern.
Rising Cancer Incidence Rate
The cancer incidence rate in India is escalating, creating a pressing demand for advanced treatment options, especially biologic therapies. Reports from the National Cancer Registry suggest that the annual incidence of cancer cases has reached approximately 1.3 million, with projections indicating a 25% increase in the next decade.
This growing patient population requires innovative treatment solutions, particularly biologics, which have shown promise in treating various cancers.Prominent players like Roche and Novartis are actively involved in the Indian market, contributing to the development and availability of biologic therapies tailored to the needs of cancer patients. Their presence and investment in clinical trials and innovative therapies play a crucial role in shaping the India Biologic Therapy Market Industry.
Government Initiatives Supporting Biologics Development
The Indian government has initiated several programs aimed at promoting the biopharmaceutical sector, which includes biologic therapies. By 2025, the Indian government's vision includes increasing the biopharmaceutical market's valuation significantly, with specific incentives for Research and Development as detailed in the Biotechnology Strategy 2022.
Additionally, the Department of Biotechnology is facilitating the establishment of bioclusters across the nation which will boost collaboration and innovation in biologics.Such proactive government support not only encourages domestic firms but also attracts foreign investment, thereby enhancing the India Biologic Therapy Market Industry's growth potential. This commitment from the government supports the establishment of a robust framework for the advancements in biologic therapies.
Increase in Healthcare Spending
India's healthcare spending has been steadily increasing, contributing to the growth of various healthcare segments, including the India Biologic Therapy Market Industry. According to the Ministry of Health and Family Welfare, the healthcare expenditure in India is projected to reach 3.5 trillion USD by 2025.
This increase in budget allocation allows for broader access to advanced treatment options such as biologic therapies, especially for chronic and complex conditions.Major pharmaceutical companies like Sanofi and AbbVie are expanding their operations in India, aiming to meet the rising demand for biologics as part of their strategy to capitalize on increased healthcare spending. Such expansions and product launches will positively impact the biologic therapy market, ensuring better access for patients across the country.
India Biologic Therapy Market Segment Insights
Biologic Therapy Market Therapy Type Insights
The Therapy Type segment within the India Biologic Therapy Market reflects a diverse array of treatment options that are transforming healthcare across the nation. Biologic therapies are increasingly recognized for their efficacy in treating complex conditions such as autoimmune diseases, cancers, and genetic disorders. Monoclonal antibodies represent a significant portion of this market, known for their ability to target specific pathways, thereby minimizing side effects and maximizing therapeutic impact.
They have been pivotal in the treatment landscape for conditions like rheumatoid arthritis and certain types of cancer, attracting substantial interest from both healthcare providers and patients. Vaccines, another critical component, play an essential role in preventive healthcare. In India, the surge in vaccine development, particularly against infectious diseases, underscores their importance in public health strategies. As the government and private sector invest in Research and Development for innovative vaccine formulations, the Indian population benefits from increased immunity, thereby decreasing disease prevalence.
Cell therapy is also gaining traction, characterized by its regenerative potential. This therapy harnesses the body's own cellular mechanisms to repair damaged tissues or organs, representing a remarkable approach particularly in the management of degenerative diseases and advanced cancers. With the advancement of technologies facilitating cell culture and manipulation, India is positioned to become a prominent player in cell therapy.Gene therapy, while still in its developmental stages, offers promising opportunities by directly addressing genetic disorders at the cellular level. The potential to rectify genetic faults before symptoms manifest could revolutionize treatment methodologies across various hereditary conditions.
The Indian regulatory environment is beginning to adapt to accommodate these innovative therapies, thereby enhancing patient access.The overall dynamics within the India Biologic Therapy Market are influenced by a combination of rising healthcare awareness, government investments in life sciences, and the increasing prevalence of chronic diseases. As healthcare systems evolve, the Therapy Type segment will continue to expand, reflecting a growing inclination towards personalized medicine that aligns patient needs with therapeutic advancements in India. The interplay of these factors will drive sustained market growth and foster a more robust ecosystem for biologic therapies in the years to come.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Biologic Therapy Market Application Insights
The India Biologic Therapy Market has a strong structure in its Application sector, which includes crucial areas like Oncology, Autoimmune Diseases, Infectious Diseases, and Cardiovascular Diseases. Oncology stands out as a critical subject because of the increased cancer prevalence in India, which is driving need for tailored medicines that improve patient outcomes. Autoimmune diseases are another important topic, indicating the rising occurrence of disorders such as rheumatoid arthritis and lupus, demanding appropriate biological therapies.
Infectious Diseases are a major focus as India's health policies strive to mitigate the impact of epidemics, fostering innovations in biologic therapies. Furthermore, the growing burden of Cardiovascular Diseases, attributed to urbanization and lifestyle changes, highlights the importance of biologic treatments tailored to improve heart health. As healthcare infrastructure improves, each of these segments presents ample opportunities for expansion and innovation, supported by favorable government initiatives aimed at elevating biopharmaceutical research and access across the region, ultimately contributing to a progressive trajectory in the India Biologic Therapy Market.
Biologic Therapy Market Route of Administration Insights
The Route of Administration segment plays a critical role in the India Biologic Therapy Market, influencing patient outcomes and treatment accessibility. Intravenous administration is widely recognized for its effectiveness in delivering biologics rapidly into the bloodstream, making it essential for acute treatments and hospital settings. Subcutaneous administration has gained prominence due to its convenience, allowing patients to self-administer therapies at home, thereby enhancing adherence and improving quality of life.
Intramuscular administration remains significant, particularly for vaccines and certain hormone therapies, due to its relatively simple technique and widespread acceptance in clinical environments.As the landscape of biologic therapies continues to evolve, advancements in formulation and delivery technologies are anticipated to further optimize these routes, fostering growth in the market. The increasing prevalence of chronic diseases and an aging population in India are expected to drive demand for these therapies, highlighting the importance of understanding the dynamics within this Route of Administration segment and its contribution to the overall India Biologic Therapy Market revenue.
Biologic Therapy Market End User Insights
The End User segment of the India Biologic Therapy Market plays a vital role in catering to the growing demand for advanced therapeutic solutions. Hospitals form a critical component of this market, equipped with the infrastructure and professional expertise to deliver biologic therapies to a diverse patient population. Clinics also contribute significantly by providing accessible outpatient care, focusing on personalized treatments and managing chronic conditions effectively.
Home Healthcare has gained prominence in recent years, reflecting a shift towards patient-centric care strategies that prioritize comfort and convenience, allowing patients to receive therapies in the comfort of their homes while reducing hospital congestion.The increasing prevalence of chronic diseases and the need for innovative treatment solutions drive the growth of these end-user sectors, presenting opportunities for advancements in biologic therapies. Additionally, the rising aging population in India further fuels the demand across these end-user categories, creating a landscape ripe for growth and innovation in the India Biologic Therapy Market. Understanding the dynamics and trends within the End User segment is crucial for stakeholders aiming to leverage the opportunities presented by this evolving market landscape.
India Biologic Therapy Market Key Players and Competitive Insights
The Indian Biologic Therapy Market has been showing dynamic growth, characterized by an increasing demand for therapeutic options that leverage biological processes to treat various chronic and complex diseases. The competitive landscape is shaped by various local and multinational companies that innovate and expand their portfolios through strategic partnerships, research and development, and targeted marketing efforts. With the government promoting initiatives to make biologic therapies more accessible and affordable, companies are vying for a foothold in this lucrative sector. The interplay of regulatory frameworks, technological advancements, and heightened patient awareness further contributes to a competitive environment where agility and innovation play crucial roles in determining market leaders.
Gilead Sciences has established a significant presence in the Indian Biologic Therapy Market through its robust portfolio focused primarily on viral infections and oncology. The company has made considerable investments in research and development to cater to the needs of Indian patients, adapting its drug formulations and delivery methods to align better with local healthcare systems. Gilead's strengths in the market include its commitment to enhancing patient access to treatments, which often includes innovative pricing models and collaborations with local healthcare providers. The company has been actively involved in partnerships aimed at enhancing diagnostic capabilities and awareness about biologic therapies, positioning itself as a leader in the sector and earning the trust of healthcare professionals and patients alike.
Novartis has also carved out a competitive position within the Indian Biologic Therapy Market, primarily focusing on therapies for conditions like cancers and immune disorders. The company's key products include monoclonal antibodies and gene therapies that have been tailored to meet the specific health needs of the Indian population. Novartis benefits from its strong research network in India, which allows it to develop localized solutions. The company has engaged in numerous strategic mergers and acquisitions to enhance its product pipeline and streamline its operations within the country. Its commitment to innovative healthcare solutions is underscored by its efforts to improve health literacy and patient engagement, fostering a loyal customer base. Through these strategic initiatives, Novartis continues to strengthen its market foothold while contributing positively to the evolving healthcare landscape in India.
Key Companies in the India Biologic Therapy Market Include:
India Biologic Therapy Market Industry Developments
Recent developments in the India Biologic Therapy Market have been marked by significant activity from leading companies such as Gilead Sciences, Novartis, Merck, and others responding to the growing demand for innovative therapies. In August 2023, Eli Lilly announced an expansion plan to establish a new production facility in India, aimed at enhancing local manufacturing capabilities for biologic therapies, reflecting the nation's increasing importance in the global supply chain.
In September 2023, Zydus Cadila launched a biosimilar of a monoclonal antibody, increasing access to affordable treatment options for patients in India. Additionally, the market saw a noteworthy merger in July 2023, when AbbVie announced its acquisition of a biotech firm specializing in new biologic therapies, enhancing its portfolio in immune-oncology.
With the overall market growing rapidly, the Indian biologics sector is projected to reach approximately USD 15 billion by 2025, driven by increased prevalence of chronic diseases and favorable government policies. In the last few years, there has been a strong push for Research and Development initiatives, with companies like Biocon and Roche making significant investments to boost innovation in the biologic therapy landscape in India.
India Biologic Therapy Market Segmentation Insights
Biologic Therapy Market Therapy Type Outlook
Biologic Therapy Market Application Outlook
Biologic Therapy Market Route of Administration Outlook
Biologic Therapy Market End User Outlook
Hospitals
Clinics
Home Healthcare
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 14.91(USD Billion) |
| MARKET SIZE 2024 | 15.7(USD Billion) |
| MARKET SIZE 2035 | 22.5(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.326% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Gilead Sciences, Novartis, Merck, Sanofi, Eli Lilly, Amgen, Johnson & Johnson, Celgene, Zydus Cadila, AbbVie, BristolMyers Squibb, Dr. Reddy's Laboratories, Pfizer, Biocon, Roche |
| SEGMENTS COVERED | Therapy Type, Application, Route of Administration, End User |
| KEY MARKET OPPORTUNITIES | Growing chronic disease prevalence, Increasing investment in R&D, Expanding healthcare infrastructure, Rising demand for personalized medicine, Government support for biosimilars |
| KEY MARKET DYNAMICS | Increasing prevalence of chronic diseases, Growing demand for personalized medicine, Rising investment in R&D, Expanding healthcare infrastructure, Regulatory shift towards biosimilars |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Biologic Therapy Market is expected to be valued at 15.7 USD Billion in 2024.
By 2035, the market is anticipated to reach a value of 22.5 USD Billion.
The anticipated CAGR for the India Biologic Therapy Market from 2025 to 2035 is 3.326%.
In 2024, the Monoclonal Antibodies segment is expected to dominate with a valuation of 5.5 USD Billion.
The Vaccines segment is projected to achieve a value of 5.9 USD Billion in 2035.
Major players in the market include Gilead Sciences, Novartis, Merck, Sanofi, and Eli Lilly.
The Cell Therapy segment is expected to be valued at 4.4 USD Billion by 2035.
The Gene Therapy segment is anticipated to be valued at 3.2 USD Billion in 2024.
Growing incidences of chronic diseases and advancements in biotechnology present significant growth opportunities.
Intense competition among key players is likely to drive innovation and enhance service offerings in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
